On the public citation graph

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

0 signed · 470 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2020.17023openalex-snapshot

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19

inferredcites →https://doi.org/10.1001/jamainternmed.2020.6615openalex-snapshot

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia

inferredcites →https://doi.org/10.1001/jamainternmed.2020.6820openalex-snapshot

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

inferredcites →https://doi.org/10.1002/art.34329openalex-snapshot

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cells

inferredcites →https://doi.org/10.1002/jlb.5ri0218-084ropenalex-snapshot

Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs

inferredcites →https://doi.org/10.1002/prp2.537openalex-snapshot

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

inferredcites →https://doi.org/10.1002/sim.1659openalex-snapshot

Goodness‐of‐fit tests for ordinal response regression models

inferredcites →https://doi.org/10.1007/s40265-020-01367-zopenalex-snapshot

Pharmaco-Immunomodulatory Therapy in COVID-19

inferredcites →https://doi.org/10.1016/j.jinf.2020.06.052openalex-snapshot

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

inferredcites →https://doi.org/10.1016/j.jinf.2021.02.023openalex-snapshot

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy

inferredcites →https://doi.org/10.1016/j.trsl.2016.11.006openalex-snapshot

JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa

inferredcites →https://doi.org/10.1016/s0140-6736(17)31618-5openalex-snapshot

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

inferredcites →https://doi.org/10.1016/s0140-6736(20)30628-0openalex-snapshot

COVID-19: consider cytokine storm syndromes and immunosuppression

inferredcites →https://doi.org/10.1016/s2213-2600(20)30556-7openalex-snapshot

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

inferredcites →https://doi.org/10.1016/s2213-2600(21)00099-0openalex-snapshot

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

inferredcites →https://doi.org/10.1056/nejmcp2009249openalex-snapshot

Mild or Moderate Covid-19

inferredcites →https://doi.org/10.1056/nejme2034982openalex-snapshot

Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled

inferredcites →https://doi.org/10.1056/nejmoa1606910openalex-snapshot

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

inferredcites →https://doi.org/10.1056/nejmoa2007764openalex-snapshot

Remdesivir for the Treatment of Covid-19 — Final Report

inferredcites →https://doi.org/10.1056/nejmoa2021436openalex-snapshot

Dexamethasone in Hospitalized Patients with Covid-19

inferredcites →https://doi.org/10.1056/nejmoa2028700openalex-snapshot

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

inferredcites →https://doi.org/10.1056/nejmoa2028836openalex-snapshot

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

inferredcites →https://doi.org/10.1056/nejmoa2030340openalex-snapshot

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

inferredcites →https://doi.org/10.1056/nejmoa2031994openalex-snapshot

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

inferredcites →https://doi.org/10.1056/nejmp2032369openalex-snapshot

FDA Approval of Remdesivir — A Step in the Right Direction

inferredcites →https://doi.org/10.1056/nejmra2026131openalex-snapshot

Cytokine Storm

inferredcites →https://doi.org/10.1093/cid/ciaa879openalex-snapshot

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

inferredcites →https://doi.org/10.1093/rheumatology/keaa587openalex-snapshot

Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study

inferredcites →https://doi.org/10.1136/bmj.m3379openalex-snapshot

A living WHO guideline on drugs for covid-19 (2020-2023)

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4087366openalex-extracted

Targeting SARS-CoV-2 Infection Through CAR-T Like Bispecific T Cell Engagers Incorporating ACE2

inferred← citeshttps://doi.org/10.2139/ssrn.4974193openalex-extracted

Effects of Jak Inhibitors in Adults Hospitalized Due to Covid-19: A Systematic Review and Individual Participant Data Meta-Analysis of Randomized Clinical Trials

inferred← citeshttps://doi.org/10.1001/jama.2021.11121openalex-snapshot

IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19

inferred← citeshttps://doi.org/10.1001/jama.2023.11260openalex-snapshot

Translating Clinical Trial Results to Clinical Practice During a Pandemic

inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.42918openalex-snapshot

Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19

inferred← citeshttps://doi.org/10.1002/14651858.cd015209openalex-snapshot

Janus kinase inhibitors for the treatment of COVID-19

inferred← citeshttps://doi.org/10.1002/art.42062openalex-snapshot

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 3

inferred← citeshttps://doi.org/10.1002/cti2.1421openalex-snapshot

Targeting SARS‐CoV ‐2 infection through CAR‐T ‐like bispecific T cell engagers incorporating ACE2

inferred← citeshttps://doi.org/10.1002/gch2.202500223openalex-snapshot

Medication, Nutrition, and Hygiene in COVID‐19 Prevention and Treatment: A Comprehensive Narrative Review

inferred← citeshttps://doi.org/10.1002/jcla.24959openalex-snapshot

Prediction of tsunami of resistance to some antibiotics is not far‐fetched which used during COVID‐19 pandemic

inferred← citeshttps://doi.org/10.1002/jgh3.12728openalex-snapshot

Impact of biologics and small molecules for inflammatory bowel disease on COVID ‐19‐related hospitalization and mortality: A systematic review and meta‐analysis

inferred← citeshttps://doi.org/10.1002/jmv.29199openalex-snapshot

Tracking antigen‐specific TCR clonotypes in SARS‐CoV‐2 infection reveals distinct severity trajectories

inferred← citeshttps://doi.org/10.1002/jmv.29456openalex-snapshot

Genomic surveillance of omicron B.1.1.529 SARS‐CoV‐2 and its variants between December 2021 and March 2023 in Tamil Nadu, India—A state‐wide prospective longitudinal study

inferred← citeshttps://doi.org/10.1002/mco2.349openalex-snapshot

Signaling pathways in macrophages: molecular mechanisms and therapeutic targets

inferred← citeshttps://doi.org/10.1002/med.21997openalex-snapshot

COVID‐19 cooling: Nanostrategies targeting cytokine storm for controlling severe and critical symptoms

inferred← citeshttps://doi.org/10.1002/minf.202400032openalex-snapshot

DIGEP‐Pred 2.0: A web application for predicting drug‐induced cell signaling and gene expression changes

inferred← citeshttps://doi.org/10.1002/ueg2.12417openalex-snapshot

Immunosuppressants exert differential effects on pan‐coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir

inferred← citeshttps://doi.org/10.1002/ueg2.12427openalex-snapshot

SARS‐CoV‐2 and immunosuppressors at cellular level: Some good news

inferred← citeshttps://doi.org/10.1007/978-3-030-87302-8_13-1openalex-snapshot

Measures of Classical and Alternative Complement Function in Serum as Markers in Critical Care

inferred← citeshttps://doi.org/10.1007/978-3-030-94740-8_4openalex-snapshot

Pharmacological Management

inferred← citeshttps://doi.org/10.1007/978-3-031-07395-3_13openalex-snapshot

Measures of Classical and Alternative Complement Function in Serum as Markers in Critical Care

inferred← citeshttps://doi.org/10.1007/978-3-031-17572-5_17openalex-snapshot

Anti-cytokine Therapy in Critical Illness: Is There a Role?

inferred← citeshttps://doi.org/10.1007/978-3-031-59815-9_22openalex-snapshot

COVID-19 Pneumonia and Cytokine Storm Syndrome

inferred← citeshttps://doi.org/10.1007/978-3-032-26000-0_15openalex-snapshot

Management of COVID-19 Patients

inferred← citeshttps://doi.org/10.1007/s00011-026-02216-7openalex-snapshot

ACT001 alleviates sepsis-induced acute lung injury by downregulating PANoptosis via the JAK2/STAT3 pathway

inferred← citeshttps://doi.org/10.1007/s00115-022-01363-6openalex-snapshot

SARS-CoV-2-Antikörper-Antwort auf die zweite COVID-19-Impfung bei neuromuskulären Patienten unter immunmodulierender Therapie

inferred← citeshttps://doi.org/10.1007/s00277-026-06769-9openalex-snapshot

Prevention, diagnosis and management of community acquired respiratory virus infections including COVID-19 in patients with cancer: 2025 updated evidence-based guideline of the infectious diseases working party (AGIHO) of the German society for hematology and medical oncology (DGHO)

inferred← citeshttps://doi.org/10.1007/s00284-024-03671-3openalex-snapshot

An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies

inferred← citeshttps://doi.org/10.1007/s00417-024-06536-4openalex-snapshot

Association between COVID-19 infection and uveitis flare in patients with Behcet’s disease, a retrospective multicenter cohort study

inferred← citeshttps://doi.org/10.1007/s00508-022-02018-xopenalex-snapshot

Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022)

inferred← citeshttps://doi.org/10.1007/s00508-022-02110-2openalex-snapshot

Tofacitinib in the treatment of ulcerative colitis

inferred← citeshttps://doi.org/10.1007/s10067-021-05884-4openalex-snapshot

Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials

inferred← citeshttps://doi.org/10.1007/s10067-022-06205-zopenalex-snapshot

Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India

inferred← citeshttps://doi.org/10.1007/s10456-024-09916-wopenalex-snapshot

Interleukin-6 drives endothelial glycocalyx damage in COVID-19 and bacterial sepsis

inferred← citeshttps://doi.org/10.1007/s10787-025-01975-9openalex-snapshot

Interleukin-10 family cytokines: key regulators and novel therapeutic targets for respiratory diseases

inferred← citeshttps://doi.org/10.1007/s11033-022-07166-xopenalex-snapshot

Blocking TNF signaling may save lives in COVID-19 infection

inferred← citeshttps://doi.org/10.1007/s11377-023-00681-8openalex-snapshot

Therapie von COVID-19 unter Berücksichtigung von Lebererkrankungen

inferred← citeshttps://doi.org/10.1007/s11606-021-07152-2openalex-snapshot

Prior Immunosuppressive Therapy and Severe Illness Among Patients Diagnosed with SARS-CoV-2: a Community-Based Study

inferred← citeshttps://doi.org/10.1007/s11739-021-02860-3openalex-snapshot

Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence

inferred← citeshttps://doi.org/10.1007/s12072-022-10306-xopenalex-snapshot

Management of hepatitis B virus reactivation due to treatment of COVID-19

inferred← citeshttps://doi.org/10.1007/s13665-023-00302-3openalex-snapshot

Current and Emerging Therapies for COVID-19 in Lung Transplantation

inferred← citeshttps://doi.org/10.1007/s15010-022-01915-7openalex-snapshot

Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort

inferred← citeshttps://doi.org/10.1007/s40121-021-00545-0openalex-snapshot

Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

inferred← citeshttps://doi.org/10.1007/s40744-022-00462-9openalex-snapshot

COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis

inferred← citeshttps://doi.org/10.1007/s42399-022-01121-4openalex-snapshot

Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19

inferred← citeshttps://doi.org/10.1007/s44179-022-00019-9openalex-snapshot

Update SARS-CoV-2 Behandlungsempfehlungen für die Intensivmedizin

inferred← citeshttps://doi.org/10.1016/b978-0-323-87539-4.00003-8openalex-snapshot

Immunology of COVID-19

inferred← citeshttps://doi.org/10.1016/b978-0-323-87539-4.00016-6openalex-snapshot

Therapeutics for COVID-19

inferred← citeshttps://doi.org/10.1016/b978-0-323-95646-8.00015-9openalex-snapshot

The COVID-19 cytokine storm and its immunomodulatory treatment

inferred← citeshttps://doi.org/10.1016/b978-0-443-14001-3.00010-8openalex-snapshot

COVID-19 and the heart

inferred← citeshttps://doi.org/10.1016/b978-0-443-15256-6.00013-1openalex-snapshot

COVID-19 and immunity

inferred← citeshttps://doi.org/10.1016/b978-0-443-18566-3.00034-7openalex-snapshot

Therapeutic options in COVID-19

inferred← citeshttps://doi.org/10.1016/b978-0-443-18566-3.00041-4openalex-snapshot

Innate immune responses in COVID-19

inferred← citeshttps://doi.org/10.1016/b978-0-443-18703-2.00022-0openalex-snapshot

COVID-19 in patients with inflammatory bowel diseases: Characteristics and guidelines

inferred← citeshttps://doi.org/10.1016/b978-0-443-18703-2.00051-7openalex-snapshot

Hemodialysis patients, effects of infections by SARS-CoV-2 and vaccine response

inferred← citeshttps://doi.org/10.1016/bs.ai.2022.08.004openalex-snapshot

Genetic susceptibility to autoimmunity—Current status and challenges

inferred← citeshttps://doi.org/10.1016/j.ajem.2022.03.036openalex-snapshot

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management

inferred← citeshttps://doi.org/10.1016/j.ard.2025.01.024openalex-snapshot

Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement

inferred← citeshttps://doi.org/10.1016/j.bcp.2022.115162openalex-snapshot

JAK inhibition as a new treatment strategy for patients with COVID-19

inferred← citeshttps://doi.org/10.1016/j.bcp.2022.115382openalex-snapshot

JAK-STAT signaling as an ARDS therapeutic target: Status and future trends

inferred← citeshttps://doi.org/10.1016/j.biopha.2022.112614openalex-snapshot

Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells

inferred← citeshttps://doi.org/10.1016/j.biopha.2022.113459openalex-snapshot

Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome

inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115959openalex-snapshot

Inhibition of SARS-CoV-2 infection and replication by Petasites hybridus CO2-extract (Ze 339)

inferred← citeshttps://doi.org/10.1016/j.bjid.2022.102347openalex-snapshot

Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of…

inferred← citeshttps://doi.org/10.1016/j.ccc.2022.02.002openalex-snapshot

Review of Anti-inflammatory and Antiviral Therapeutics for Hospitalized Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2

inferred← citeshttps://doi.org/10.1016/j.ccm.2022.11.009openalex-snapshot

Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia

inferred← citeshttps://doi.org/10.1016/j.ccm.2022.11.014openalex-snapshot

SARS-CoV-2 Infection and COVID-19 in Children

inferred← citeshttps://doi.org/10.1016/j.cell.2021.11.033openalex-snapshot

SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis

inferred← citeshttps://doi.org/10.1016/j.chmed.2026.02.016openalex-snapshot

Efficacy and safety of Toujie Quwen Granules in patients infected with SARS-CoV-2: A prospective cohort study of 156 cases

inferred← citeshttps://doi.org/10.1016/j.chstcc.2023.100030openalex-snapshot

Acute Respiratory Failure From Early Pandemic COVID-19

inferred← citeshttps://doi.org/10.1016/j.clim.2021.108849openalex-snapshot

A hitchhiker's guide through the COVID-19 galaxy

inferred← citeshttps://doi.org/10.1016/j.cnc.2024.01.002openalex-snapshot

Understanding the Evolving Pathophysiology of Coronavirus Disease 2019 and Adult Nursing Management

inferred← citeshttps://doi.org/10.1016/j.compbiomed.2024.108574openalex-snapshot

Exploring the immune characteristions of CRKP pneumonia at single-cell level

inferred← citeshttps://doi.org/10.1016/j.coviro.2021.11.002openalex-snapshot

Host cell-intrinsic innate immune recognition of SARS-CoV-2

inferred← citeshttps://doi.org/10.1016/j.curtheres.2021.100639openalex-snapshot

Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?

inferred← citeshttps://doi.org/10.1016/j.cyto.2021.155719openalex-snapshot

Randomized trial drug controlled compendious transcriptome analysis supporting broad and phase specific therapeutic potential of multiple candidates in COVID-19

inferred← citeshttps://doi.org/10.1016/j.cyto.2023.156433openalex-snapshot

Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients

inferred← citeshttps://doi.org/10.1016/j.cytogfr.2023.07.002openalex-snapshot

Recent progress and prospects for anti-cytokine therapy in preclinical and clinical acute lung injury

inferred← citeshttps://doi.org/10.1016/j.diagmicrobio.2024.116643openalex-snapshot

The development of therapeutics and vaccines against COVID-19.

inferred← citeshttps://doi.org/10.1016/j.dmpk.2021.100439openalex-snapshot

Synthesis and evaluation of tofacitinib analogs designed to mitigate metabolic activation

inferred← citeshttps://doi.org/10.1016/j.drudis.2024.104126openalex-snapshot

An overview of the development of pharmacotherapeutics targeting SARS-CoV-2

inferred← citeshttps://doi.org/10.1016/j.drup.2021.100794openalex-snapshot

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104387openalex-snapshot

Gaps and opportunities in sepsis translational research

inferred← citeshttps://doi.org/10.1016/j.eclinm.2021.101242openalex-snapshot

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial

inferred← citeshttps://doi.org/10.1016/j.eclinm.2022.101362openalex-snapshot

Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group

inferred← citeshttps://doi.org/10.1016/j.eclinm.2022.101489openalex-snapshot

Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials

inferred← citeshttps://doi.org/10.1016/j.ejca.2022.11.030openalex-snapshot

AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants

inferred← citeshttps://doi.org/10.1016/j.ejim.2022.05.014openalex-snapshot

Treatment strategies of COVID-19: A rheumatology perspective

inferred← citeshttps://doi.org/10.1016/j.ejim.2023.07.037openalex-snapshot

Immune regulators for the treatment of COVID-19: A critical appraisal after two years

inferred← citeshttps://doi.org/10.1016/j.ejmcr.2021.100019openalex-snapshot

Synthesis and evaluation of hydrogen peroxide sensitive tofacitinib prodrugs

inferred← citeshttps://doi.org/10.1016/j.emc.2022.12.004openalex-snapshot

Management of Coronavirus Disease-2019 Infection in Pregnancy

inferred← citeshttps://doi.org/10.1016/j.eprac.2022.07.006openalex-snapshot

New Insights on Effects of Glucocorticoids in Patients With SARS-CoV-2 Infection

inferred← citeshttps://doi.org/10.1016/j.heliyon.2022.e12333openalex-snapshot

Model exploration for discovering COVID-19 targeted traditional Chinese medicine

inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e34244openalex-snapshot

A deep learning drug screening framework for integrating local-global characteristics: A novel attempt for limited data

inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e38229openalex-snapshot

Efficacy and safety of tofacitinib on COVID-19 patients: A systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1016/j.idc.2022.02.001openalex-snapshot

Pharmacologic Treatment and Management of Coronavirus Disease 2019

inferred← citeshttps://doi.org/10.1016/j.idc.2022.07.002openalex-snapshot

Management of Severe and Critical COVID-19 Infection with Immunotherapies

inferred← citeshttps://doi.org/10.1016/j.infpip.2022.100267openalex-snapshot

Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study

inferred← citeshttps://doi.org/10.1016/j.intimp.2021.108027openalex-snapshot

Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials

inferred← citeshttps://doi.org/10.1016/j.intimp.2022.108536openalex-snapshot

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

inferred← citeshttps://doi.org/10.1016/j.intimp.2023.110565openalex-snapshot

Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19

inferred← citeshttps://doi.org/10.1016/j.isci.2022.104415openalex-snapshot

Pearson’s patterns correlational of clinical risks at admissions with hospitalization outcomes during initial COVID-19 outbreak

inferred← citeshttps://doi.org/10.1016/j.jaad.2021.11.043openalex-snapshot

Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium

inferred← citeshttps://doi.org/10.1016/j.jaci.2021.08.004openalex-snapshot

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition

inferred← citeshttps://doi.org/10.1016/j.jaci.2021.11.019openalex-snapshot

The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression

inferred← citeshttps://doi.org/10.1016/j.jclepro.2022.135826openalex-snapshot

Effective utilization of waste plastics towards sustainable control of mosquito

inferred← citeshttps://doi.org/10.1016/j.jcmgh.2024.101447openalex-snapshot

Tofacitinib Mitigates the Increased SARS-CoV-2 Infection Susceptibility Caused by an IBD Risk Variant in the PTPN2 Gene

inferred← citeshttps://doi.org/10.1016/j.jcrc.2024.154892openalex-snapshot

Antisense therapy to block the Kallikrein-kinin pathway in COVID-19: The ASKCOV randomized controlled trial

inferred← citeshttps://doi.org/10.1016/j.jhep.2022.07.008openalex-snapshot

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

inferred← citeshttps://doi.org/10.1016/j.jhepr.2024.101074openalex-snapshot

CXCR6+CD69+ CD8+ T cells in ascites are associated with disease severity in patients with cirrhosis

inferred← citeshttps://doi.org/10.1016/j.jmii.2022.08.005openalex-snapshot

Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trials

inferred← citeshttps://doi.org/10.1016/j.jocmr.2024.101121openalex-snapshot

Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints

inferred← citeshttps://doi.org/10.1016/j.lfs.2022.120809openalex-snapshot

Recent clinical findings on the role of kinase inhibitors in COVID-19 management

inferred← citeshttps://doi.org/10.1016/j.liver.2021.100026openalex-snapshot

COVID-19 in liver transplant recipients

inferred← citeshttps://doi.org/10.1016/j.mcna.2022.08.002openalex-snapshot

Care of the Seriously Ill Patient with SARS-CoV-2

inferred← citeshttps://doi.org/10.1016/j.mjafi.2022.06.020openalex-snapshot

Management of COVID-19: A comprehensive and practical approach

inferred← citeshttps://doi.org/10.1016/j.mmifmc.2021.11.005openalex-snapshot

COVID-19 : les thérapeutiques

inferred← citeshttps://doi.org/10.1016/j.monrhu.2021.11.002openalex-snapshot

En quoi la Covid-19 concerne la prise en charge des rhumatismes inflammatoires ? Place de la vaccination selon les cas

inferred← citeshttps://doi.org/10.1016/j.phrs.2021.105848openalex-snapshot

Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity

inferred← citeshttps://doi.org/10.1016/j.phymed.2023.155141openalex-snapshot

Hexahydrocurcumin from Zingiberis rhizoma attenuates lipopolysaccharide-induced acute pneumonia through JAK1/STAT3 signaling pathway

inferred← citeshttps://doi.org/10.1016/j.rdc.2024.09.003openalex-snapshot

SARS-CoV-2 Infection and COVID-19 in Children

inferred← citeshttps://doi.org/10.1016/j.rmed.2021.106620openalex-snapshot

Rationale and design of a mechanistic clinical trial of JAK inhibition to prevent ventilator-induced diaphragm dysfunction

inferred← citeshttps://doi.org/10.1016/j.scitotenv.2021.150873openalex-snapshot

COVID-19 and antimicrobial resistance: A cross-study

inferred← citeshttps://doi.org/10.1016/j.smim.2021.101508openalex-snapshot

Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion

inferred← citeshttps://doi.org/10.1016/j.smim.2021.101524openalex-snapshot

Myeloid dysregulation and therapeutic intervention in COVID-19

inferred← citeshttps://doi.org/10.1016/j.tim.2022.12.008openalex-snapshot

Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation

inferred← citeshttps://doi.org/10.1016/j.trre.2023.100788openalex-snapshot

Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant…

inferred← citeshttps://doi.org/10.1016/s0140-6736(22)01109-6openalex-snapshot

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

inferred← citeshttps://doi.org/10.1016/s2211-9698(21)44374-8openalex-snapshot

10.1016/s2211-9698(21)44374-8

inferred← citeshttps://doi.org/10.1016/s2213-2600(21)00331-3openalex-snapshot

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

inferred← citeshttps://doi.org/10.1016/s2213-2600(22)00006-6openalex-snapshot

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

inferred← citeshttps://doi.org/10.1016/s2213-2600(22)00365-4openalex-snapshot

Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?

inferred← citeshttps://doi.org/10.1016/s2213-2600(25)00055-4openalex-snapshot

Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials

inferred← citeshttps://doi.org/10.1016/s2665-9913(21)00247-2openalex-snapshot

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses

inferred← citeshttps://doi.org/10.1016/s2665-9913(21)00322-2openalex-snapshot

Therapeutic implications of ongoing alveolar viral replication in COVID-19

inferred← citeshttps://doi.org/10.1016/s2665-9913(21)00325-8openalex-snapshot

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative

inferred← citeshttps://doi.org/10.1016/s2665-9913(21)00353-2openalex-snapshot

Who, what, and when—effective therapy for severe COVID-19

inferred← citeshttps://doi.org/10.1016/s2665-9913(22)00068-6openalex-snapshot

No perfect therapy for the imperfect COVID-19 cytokine storm

inferred← citeshttps://doi.org/10.1017/erm.2022.10openalex-snapshot

COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients

inferred← citeshttps://doi.org/10.1021/acsomega.2c02794openalex-snapshot

Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice

inferred← citeshttps://doi.org/10.1038/s41375-022-01578-1openalex-snapshot

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

inferred← citeshttps://doi.org/10.1038/s41380-022-01741-1openalex-snapshot

Neurogenesis is disrupted in human hippocampal progenitor cells upon exposure to serum samples from hospitalized COVID-19 patients with neurological symptoms

inferred← citeshttps://doi.org/10.1038/s41385-021-00464-wopenalex-snapshot

Immune interventions in COVID-19: a matter of time?

inferred← citeshttps://doi.org/10.1038/s41392-021-00792-0openalex-snapshot

Myeloid cells in COVID-19 microenvironment

inferred← citeshttps://doi.org/10.1038/s41392-022-01230-5openalex-snapshot

CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis

inferred← citeshttps://doi.org/10.1038/s41392-023-01468-7openalex-snapshot

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

inferred← citeshttps://doi.org/10.1038/s41392-024-02049-yopenalex-snapshot

Neutrophil diversity and function in health and disease

inferred← citeshttps://doi.org/10.1038/s41467-022-30699-5openalex-snapshot

SARS-CoV-2 accessory proteins reveal distinct serological signatures in children

inferred← citeshttps://doi.org/10.1038/s41467-023-42320-4openalex-snapshot

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

inferred← citeshttps://doi.org/10.1038/s41540-023-00269-6openalex-snapshot

A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions

inferred← citeshttps://doi.org/10.1038/s41573-023-00672-yopenalex-snapshot

Therapeutic strategies for COVID-19: progress and lessons learned

inferred← citeshttps://doi.org/10.1038/s41577-022-00734-zopenalex-snapshot

Host-directed immunotherapy of viral and bacterial infections: past, present and future

inferred← citeshttps://doi.org/10.1038/s41577-023-00877-7openalex-snapshot

Protein kinases: drug targets for immunological disorders

inferred← citeshttps://doi.org/10.1038/s41579-022-00839-1openalex-snapshot

Innate immune evasion strategies of SARS-CoV-2

inferred← citeshttps://doi.org/10.1038/s41584-022-00755-xopenalex-snapshot

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations

inferred← citeshttps://doi.org/10.1038/s41591-021-01499-zopenalex-snapshot

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

inferred← citeshttps://doi.org/10.1038/s41591-021-01500-9openalex-snapshot

Calming the cytokine storm in COVID-19

inferred← citeshttps://doi.org/10.1038/s41591-021-01643-9openalex-snapshot

A guide to immunotherapy for COVID-19

inferred← citeshttps://doi.org/10.1038/s41598-022-26471-wopenalex-snapshot

Development and validation of a predictive scoring system for in-hospital mortality in COVID-19 Egyptian patients: a retrospective study

inferred← citeshttps://doi.org/10.1038/s41598-023-48422-9openalex-snapshot

Amplification of poly(I:C)-induced interleukin-6 production in human bronchial epithelial cells by priming with interferon-γ

inferred← citeshttps://doi.org/10.1055/a-1643-4209openalex-snapshot

Klinischer Nutzen von Tocilizumab und anderen immunmodulatorischen Substanzen bei COVID-19

inferred← citeshttps://doi.org/10.1055/a-1652-2638openalex-snapshot

Management einer persistierenden Kolitis nach erfolgreicher Immuntherapie eines nicht-kleinzelligen Karzinoms der Lunge

inferred← citeshttps://doi.org/10.1055/a-1714-4124openalex-snapshot

Diabetes und Nierenerkrankungen bei COVID-19

inferred← citeshttps://doi.org/10.1055/a-1934-1989openalex-snapshot

S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie – AWMF-Registernummer: 021-031 – Stand 15. Juni 2022

inferred← citeshttps://doi.org/10.1055/s-0042-1757634openalex-snapshot

COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment

inferred← citeshttps://doi.org/10.1055/s-0044-1787991openalex-snapshot

Acute Management of Sepsis beyond 24 Hours

inferred← citeshttps://doi.org/10.1056/evidoa2200145openalex-snapshot

Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis

inferred← citeshttps://doi.org/10.1056/evidra2200118openalex-snapshot

Immune Modulation in Sepsis, ARDS, and Covid-19 — The Road Traveled and the Road Ahead

inferred← citeshttps://doi.org/10.1056/nejme2108667openalex-snapshot

JAK Inhibitors — More Than Just Glucocorticoids

inferred← citeshttps://doi.org/10.1073/pnas.2119893119openalex-snapshot

COVID-19 therapeutics: Challenges and directions for the future

inferred← citeshttps://doi.org/10.1080/00325481.2022.2033563openalex-snapshot

Therapeutic role of immunomodulators during the COVID-19 pandemic– a narrative review

inferred← citeshttps://doi.org/10.1080/02652048.2023.2175924openalex-snapshot

Dry powder formulation of azithromycin for COVID-19 therapeutics

inferred← citeshttps://doi.org/10.1080/09537104.2022.2131751openalex-snapshot

Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib

inferred← citeshttps://doi.org/10.1080/13543784.2022.2120801openalex-snapshot

Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics

inferred← citeshttps://doi.org/10.1080/13543784.2024.2315128openalex-snapshot

Investigational pharmacological agents for the treatment of ARDS

inferred← citeshttps://doi.org/10.1080/14656566.2022.2035360openalex-snapshot

Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)

inferred← citeshttps://doi.org/10.1080/14656566.2022.2140041openalex-snapshot

Treatment of severe COVID-19: an evolving paradigm

inferred← citeshttps://doi.org/10.1080/14728214.2022.2105833openalex-snapshot

Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials

inferred← citeshttps://doi.org/10.1080/14740338.2023.2181339openalex-snapshot

Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature

inferred← citeshttps://doi.org/10.1080/14740338.2023.2223955openalex-snapshot

Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)

inferred← citeshttps://doi.org/10.1080/14779072.2022.2132230openalex-snapshot

Managing Covid-19 in patients with heart failure: current status and future prospects

inferred← citeshttps://doi.org/10.1080/14787210.2022.2004120openalex-snapshot

Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials

inferred← citeshttps://doi.org/10.1080/14787210.2023.2151438openalex-snapshot

Infliximab as a potential treatment for COVID-19

inferred← citeshttps://doi.org/10.1080/1744666x.2022.2014323openalex-snapshot

The infection risks of JAK inhibition

inferred← citeshttps://doi.org/10.1080/26895293.2021.1977186openalex-snapshot

SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey

inferred← citeshttps://doi.org/10.1093/ajhp/zxad152openalex-snapshot

An update on drug-drug interactions for care of the acutely ill in the era of COVID-19

inferred← citeshttps://doi.org/10.1093/bfgp/elad051openalex-snapshot

From bench to bedside: potential of translational research in COVID-19 and beyond

inferred← citeshttps://doi.org/10.1093/bioinformatics/btaf498openalex-snapshot

Integrating population-level and cell-based signatures for drug repositioning

inferred← citeshttps://doi.org/10.1093/cid/ciac639openalex-snapshot

Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19)

inferred← citeshttps://doi.org/10.1093/cid/ciac724openalex-snapshot

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)

inferred← citeshttps://doi.org/10.1093/jpids/piad116openalex-snapshot

Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce

inferred← citeshttps://doi.org/10.1093/ofid/ofab588openalex-snapshot

Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019

inferred← citeshttps://doi.org/10.1093/ofid/ofac381openalex-snapshot

Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials

inferred← citeshttps://doi.org/10.1093/ofid/ofac655openalex-snapshot

Immune-Based Therapy for Hospitalized Patients With COVID-19 and Risk of Secondary Infections: A Systematic Review and Meta-analysis

inferred← citeshttps://doi.org/10.1093/ofid/ofad525openalex-snapshot

Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial

inferred← citeshttps://doi.org/10.1093/pcmedi/pbae015openalex-snapshot

COVID-19: from immune response to clinical intervention

inferred← citeshttps://doi.org/10.1093/rheumatology/keac142openalex-snapshot

Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry

inferred← citeshttps://doi.org/10.1097/bor.0000000000000822openalex-snapshot

Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate

inferred← citeshttps://doi.org/10.1097/cce.0000000000000702openalex-snapshot

Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study

inferred← citeshttps://doi.org/10.1097/ccm.0000000000005682openalex-snapshot

Randomized Phase 3 Trial of Ruxolitinib for COVID-19–Associated Acute Respiratory Distress Syndrome*

showing the first 200 of 441 · page through all 441

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.